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Abstract
Purpose: Quantification of mRNA has historically been done by reverse transcription polymerase chain reaction (RT-PCR).
Recently, a robust method of detection of mRNA utilizing in situ hybridization has been described that is linear and shows
high specificity with low background. Here we describe the use of the AQUA method of quantitative immunofluorescence
(QIF) for measuring mRNA in situ using ESR1 (the estrogen receptor alpha gene) in breast cancer to determine its predictive
value compared to Estrogen Receptor a (ER) protein.
Methods: Messenger RNA for ER (ESR1) and Ubiquitin C (UbC) were visualized using RNAscope probes and levels were
quantified by quantitative in situ hybridization (qISH) on two Yale breast cancer cohorts on tissue microarrays. ESR1 levels
were compared to ER protein levels measured by QIF using the SP1 antibody.
Results: ESR1 mRNA is reproducibly and specifically measurable by qISH on tissue collected from 1993 or later. ESR1 levels
were correlated to ER protein levels in a non-linear manner on two Yale cohorts. High levels of ESR1 were found to be
predictive of response to tamoxifin.
Conclusion: Quantification of mRNA using qISH may allow assessment of large cohorts with minimal formalin fixed, paraffin
embedded tissue. Exploratory data using this method suggests that measurement of ESR1 mRNA levels may be predictive of
response to endocrine therapy in a manner that is different from the predictive value of ER.
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Introduction
Despite the usefulness of ER as a predictive marker for
endocrine therapy 50% of ER positive patients still recur,
indicating a need for additional predictive biomarkers for
endocrine therapy [1]. Genomic technologies have allowed the
search for new potential biomarkers beyond the traditional
protein-based Immunohistochemistry (IHC) markers to gene
expression signatures using messenger RNA (mRNA) to provide
prognostic or predictive information [2]. One such example is the
Oncotype DX assay that uses 21 genes to determine a recurrence
score to quantify the risk of distant recurrence in tamoxifen-
treated, lymph node negative, ER positive breast cancer [3,4,5].
These results suggest that assessment of mRNA levels may carry
information regarding response to therapy that could be comple-
mentary or unique from the information conveyed by the
assessment of protein expression.
Assessment of mRNA expression signatures allows for the
comparison of thousands of genes at a time. As a result, mRNA
expression-based signatures, like the Agendia Mammaprint test
and the PAM50 have shown that better patient stratification can
be achieved by looking at many genes [6,7]. However, recently,
Paik and colleagues have suggested that even looking at the
mRNA from a single gene could show predictive power [8]. This
observation raises the concept of measurement of mRNA in the
same way we measure protein, that is, using in situ methods.
Recently a novel mRNA in situ hybridization (ISH) technique
called RNAscope (Advanced Cell Diagnostics, Inc., Hayward, CA)
has been developed that can be used to detect RNA transcripts on
formalin-fixed paraffin embedded (FFPE) tissue [9,10,11,12,13].
This method provides the opportunity to measure mRNA in large
collections of FFPE tissue where conventional methods of
obtaining mRNA would be limiting. However, in order for in
situ methods to have value similar to RT-PCR, the analysis must
be combined with a quantitative tool. Here we modified the
AQUA method for quantitative measurement of protein to
combine it with the RNAscope method to quantify ER mRNA
(ESR1) in situ and to compare to ER protein levels determined by
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e36559quantitative immunofluorescence (QIF) on two breast cancer
cohorts.
Results
RNAscope Assay Validation
The RNAscopeH assay for ESR1, UbC, and DapB was first
performed on serial sections of a control TMA containing a panel
of ER positive and ER negative breast cancer cell lines in 2-fold
redundancy and quantified using AQUA (Fig. 1a). The method of
quantitative in situ hybridization (qISH) gave AQUA scores for
ESR1 ranging from 3–17 with threshold for positivity by the assay
corresponding to an AQUA score of 4. As expected, MDA-MB-
468, SKBR3, BT20, and UACC812 lines were all negative and
ZR75-1, BT474, MCF7, and MDA-MB-361 lines were positive
for ESR1. The same cell lines were negative or positive respectively
for ER protein expression as determined by Western blot with SP1
(Fig. 1b). Representative images for ESR1, UbC, and DapB as well
as the tumor mask generated by cytokeratin staining are shown in
Fig. 1c.
The qISH of ESR1 and UbC by this assay was highly
reproducible (R
2 of 0.86 and 0.79 respectively) on serial sections
of a control array with 71 breast cancer cases (YTMA 209) run in
2 independent experiments (Fig. 1d). Additionally, AQUA scores
for ESR1 were compared for 2 independent cores from the YTMA
128 cohort (R
2 of 0.74) and from the YTMA 130, (R
2 of 0.54,
Fig. 1e) illustrating the level of heterogeneity of ESR1 expression
between different cores of the same tumor.
mRNA Quality for RNAscope on FFPE Tissue is
Dependent on Tissue Age
Previous reports have shown that RNA quality extracted from
FFPE tissue is affected by the duration of FFPE tissue block storage
[14]. To determine the patient tissue viable for analysis on YTMA
130, AQUA scores for UbC (positive control probe with expression
expected in every tumor) were averaged by year. A time series test
showed a significant increase in AQUA score (p=0.0003) with an
evident breakpoint at 1993 (Fig. 2a). A similar analysis for ESR1 on
ER positive cases from YTMA 130 identified also showed
a significant increasing trend (p=0.0111) with higher AQUA
scores seen in the more recent the tissue samples (Fig. 2b).
Therefore only cases from 1993 or later were included in
subsequent analysis and are identified as the YTMA 130 Subset.
There were no statistically significant differences in the clinico-
pathological characteristics between the complete cohort and
YTMA 130 Subset (Table 1). Comparison of the average AQUA
score of ER protein in ER positive cases demonstrated no trend
from 1975–2003 (Fig. 2c).
Correlation Between ER mRNA and ER Protein
The qISH assay allows comparison of the level of ER mRNA to
ER protein both quantified on a continuous scale using AQUA on
serial sections of the breast cancer cohorts. The YTMA-128
cohort contained cases from 2002–2006 therefore all cases with
scores for both ER SP1 (protein) and ESR1 were used in the
comparison, whereas only cases from the YTMA-130 Subset were
used. The natural log of the nuclear SP1 protein AQUA scores
was used to convert the scores to the same scale as the ESR1
AQUA scores. Both cohorts demonstrate a positive, but non-linear
correlation between ER mRNA and protein levels (Fig. 3a and b).
Examples of the staining patterns observed from four cases on
YTMA 128 are shown in Figure 3c. Case 1 demonstrates low
levels of both ER mRNA and protein. Cases 2 and 3 have similar
levels of ER mRNA, but Case 2 has low levels of protein whereas
Case 3 has very high protein levels. Case 4 illustrates a less
common example of high mRNA with moderate protein
expression levels.
ESR1 Predicts Response to Tamoxifen
The ESR1 AQUA scores from the 2 cores of YTMA 130 Subset
(from 1993 and later) were averaged and the median AQUA score
was used to define ESR1 high and ESR1 low patient populations.
Kaplan-Meier analysis using recurrence free survival showed no
prognostic value for ESR1 (Fig. 4a). As previously described [15],
ER positivity determined by QIF for ER protein expression is
prognostic, where ER positive patients have a higher probability
for recurrence free survival, p=0.0098 (Fig. 4d). Interestingly,
ESR1 high patients treated with tamoxifen have significantly better
(p=0.0067) recurrence free survival compared to ESR1 high
patients who did not receive tamoxifen, indicating ESR1 status is
predictive for response to endocrine therapy (Fig. 4b). This was not
seen in the ESR1 low patient population (Fig. 4c). ER positivity
determined by protein expression trended towards prediction of
response to endocrine therapy, but did not reach statistical
significance (Fig. 4e). When the variables were combined in a Cox
proportional hazards multivariate analysis ER protein expression
remained significant independent of age, tumor size, nodal status,
PgR, HER2, and ESR1 status (Table 2). A Cox model with just ER
and ESR1 was similar where ER was significant and independent
of ESR1 (p=0.0028, Table 3).
Discussion
In this work, we show that the RNAscope method of qISH is
specific for ESR1 and can be combined with the AQUA method of
analysis to measure the levels of mRNA. The qISH approach also
allows assessment of reproducibility between runs and between
histospots on a TMA. Unlike more common RT-PCR based
methods for measurement of mRNA, the qISH method allows
assessment in epithelial tissue only and conserves potential spatial
information while normalizing for the amount of epithelium
present in the specimen. Since the method does not require
extraction or microdissection, it allows large cohort analysis on
minimal tissue specimens (a single histospot on a TMA). We
believe these advantages could broadly increase the specimen
range of tissues available for mRNA analysis.
Using this qISH assay, we observed a non-linear relationship
between ER mRNA and protein (Fig. 3). While previous work has
largely shown proportional relationships between ER protein and
ESR1 mRNA [8,16,17,18]; in both cohorts we found a pro-
portional, but non-linear relationship. Specifically, cases with
relatively low levels of ESR1 (AQUA score ,5) demonstrated
a wide range of ER protein expression whereas the majority of
cases with the highest ESR1 levels were also among the highest
expressers of ER protein. We did not observe a single case with
high levels of ESR1 that was negative for ER protein expression.
However there were cases with high ER protein expression that
were right around the threshold of detection for ESR1 by this
assay. We believe these observations reflect differences in stability
of ER protein versus ESR1 mRNA. Future studies will be required
to test this hypothesis.
While ER protein levels have been shown many times to be
both predictive and prognostic, less data was available on mRNA.
The recent reporting of ESR1 mRNA as part of the Oncotype DX
test has raised the issue of predictive value since the test is now in
broad clinical use. Members of the Genomic Health group and
others recently reanalyzed the B14 data to show that, in fact,
mRNA for ESR1 is predictive when measured by their RT-PCR
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PLoS ONE | www.plosone.org 3 May 2012 | Volume 7 | Issue 5 | e36559Figure 1. Validation of the RNAscope assay. (A) Average AQUA score distributions of the RNAscope assay for ESR1, UbC, and DapB performed
on serial sections of the control array (YTMA 188) are shown in order of increasing ESR1. Error bars represent standard deviation for those cell lines
where both cores were available for analysis. (B) 20 mg total cell lysate from MDA-MB-468, SKBR3, BT20, UACC812, ZR75-1, BT474, MCF7 and MDA-MB-
231 were probed with ER SP1 antibody by Western blot. b-Tubulin served as a loading control. (C) Representative images are shown for ESR1 negative
cell lines BT20 and UACC812 and ESR1 positive cell lines ZR75-1, MCF7 and MDA-MB-361 with the corresponding UbC positive control, DapB negative
control, and tumor mask compartment generated using cytokeratin. (D) Reproducibility of the assay between serial sections of the same TMA core is
shown on the breast index array (YTMA 209) for ESR1 and UbC. (E) Reproducibility of ESR1 between 2 patient cores on YTMA 128 (top) and YTMA 130
(bottom).
doi:10.1371/journal.pone.0036559.g001
Figure 2. mRNA quality is dependent on tissue age. (A) Average AQUA scores for the UbC positive control by year. Time series testing after
simple exponential smoothing demonstrates a statistically significant upward trend with an obvious split at 1993 (p=0.0003). (B) Average AQUA
scores by year for ESR1 are shown only for patients with positive Path ER protein status. Time series testing after simple exponential smoothing
demonstrates a statistically significant upward trend (p=0.0111). (C) Average nuclear AQUA scores by year for are shown ER protein determined with
SP1 only for patients with positive Path ER protein status and demonstrate no significant trend over time. Error bars represent standard deviation.
doi:10.1371/journal.pone.0036559.g002
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illustrating the non-linear relationship between mRNA and
protein. We also show that that prognostic value of ER is
independent of the mRNA levels in multivariate models.
While these observations are provocative, the study has a series
of limitations that must be considered. Perhaps the most significant
is that the outcome analysis could only be performed in a single
cohort that was further limited by the fact that only cases after
1993 could be used. This cohort was also limited by the fact that is
a retrospective collection rather than a prospective trial, and as
such, treatment was not controlled and homogeneous. Although
a second cohort was assessed, which supported the conclusion of
a non-linear relationship; no survival analysis could be performed
on this cohort as the collection is too recent for meaningful follow-
up. Another limitation of this study is the choice of cut-point that
defined ESR1 high versus ESR1 low patient populations. We chose
the median as an objective cut-point even though it may not be the
most biologically relevant. Finally, the analyses were done on
tissue from a single site (Yale New Haven Hospital). While we
show that the data prior to 1993 shows degradation, we cannot
conclude that is a function of tissue age since it is possible there
was a change in some laboratory reagent that year that resulted in
a change of stability of the mRNA is the FFPE material. Finally,
this material, like all historical FFPE material is subject to pre-
analytic variation. We are unaware of any systematic assessment of
the effects of pre-analytic variation on mRNA measured in situ.W e
look forward to testing the assay on material from other sites and
on material that has controlled pre-analytic variables (Neumeister
et al, under review).
In summary, we show that qISH can be used to reproducibly
and quantitatively measure mRNA in TMA sections. The analysis
of ESR1 and ER on the same TMA histospots suggests a non-
linear relationship and that ESR1 is predictive of response to
endocrine therapy. However, given the retrospective cohorts used
in these discovery-based studies, this work must be considered
exploratory. We look forward to applying this technology to large
multi-institutional cooperative group studies.
Materials and Methods
Patient Cohorts
Two tissue microarray (TMA) cohorts of archival breast cancer
samples from Yale were used in this study. The Yale Sentinel
Node Cohort, called YTMA 128 (patients diagnosed from 2002–
2006, n=238) was accrued by Dr. Donald Lannin. An in-
dependent and non-overlapping cohort, called YTMA 130, from
patients diagnosed from 1976–2005, (n=524) was accrued by Dr.
Bruce Haffty. Clinicopathologic characteristics of both cohorts are
found in Table 1.
RNA in Situ Hybridization
ISH for ER mRNA was performed using the RNAscope FFPE
assaykitaccordingtothemanufacturer’sinstructionswithmodifica-
tions for fluorescence detection of transcripts using Cy5-tyramide.
Briefly,5 mmthickTMAsectionsweretreatedwithheatandprotease
digestionfollowedbyhybridizationwithamixturecontainingtarget
probestoESR1,thehousekeepinggeneUbiquitinC(UbC)asapositive
controlorthebacterialgeneDapBasanegativecontrol.ESR1orUbC
specific hybridization signals were detected with Cy5-tyramide.
Sectionsweretheincubatedwith0.3%bovineserumalbumin(BSA)
in 0.1 mol/L of Tris-buffered saline (triethanolamine-buffered
saline, pH 8) for 30 minutes at room temperature followed by
incubation with a wide-spectrum rabbit anti-cow cytokeratin
antibody (Z0622 1:100, DAKO Corp, Carpinteria, CA) in BSA/
tris-bufferedsalinefor1houratroomtemperature.Thecytokeratin
signal was detected with Alexa 546 conjugated goat anti-rabbit
(1:100,MolecularProbes,Eugene,OR)incubatedfor1houratroom
temperature.SlideswerethenmountedusingProlongGoldplus4,6-
diamidino-2-phenylindole (DAPI).
Western Blot Analysis
Cells were harvested in NP-40 lysis buffer (1% NP-40, 20 mM
Tris-HCl, 137 mM NaCl, 10% glycerol, 2 mM EDTA, 1 mM
DTT, 1 x Complete midi-EDTA protease inhibitor cocktail
(Roche Diagnostics, Indianapolis, IN), 1 mM sodium orthovana-
date). Lysate concentrations were measured using Bio-Rad
(Hercules, CA) reagent, and lysate was loaded onto NuPAGE 4–
12% Bis-tris gels and transferred to 0.2 mm nitrocellulose
membrane (Bio-Rad). Membranes were blocked in 5% milk,
TBS, and 1% Tween for 1 hour at room temperature. Primary
antibody SP1 (1:1000, Thermo Scientific, Rockford, IL) was
added to TBS/Tween and incubated overnight at 4uC. Primary
Table 1. Cohorts characteristics and Post-1993 Subset from
YTMA-130.
Characteristic YTMA 128 YTMA 130 YTMA 130 Subset
No. (%) No. (%) No. (%) p-value
All patients 238 524 226
Age, years
,50 75 (31.5) 152 (29.0) 73 (32.3)
$50 147 (61.8) 293 (55.9) 153 (67.7) 0.3151
Unknown 16 (6.7) 79 (15.1) 0 (0)
Nodal status
Positive 72 (30.3) 72 (13.7) 42 (18.6)
Negative 151 (63.4) 253 (48.3) 146 (64.6) 0.4804
Unsampled/unknown 15 (6.3) 199 (38.0) 38 (16.8)
Tumor size
,2 cm 143 (60.1) 267 (51.0) 145 (64.2)
2–5 cm 72 (30.3) 124 (23.7) 69 (30.5) 0.4469
.5 cm 10 (4.2) 2 (0.4) 0 (0)
Unknown 13 (5.5) 131 (25.0) 12 (5.3)
ER (IHC)
Positive (1–3) 162 (68.1) 220 (42.0) 125 (53.3)
Negative (0) 39 (16.4) 169 (32.3) 87 (38.5) 0.4823
Unknown 37 (15.5) 135 (25.8) 14 (6.2)
PgR (IHC)
Positive (1–3) 142 (59.7) 37 (7.1) 28 (12.4)
Negative (0) 59 (24.8) 349 (66.6) 182 (80.5) 0.0804
Unknown 37 (15.5) 138 (23.3) 16 (7.1)
Her2 (IHC)
Positive (2–3) 56 (23.5) 39 (7.4) 26 (11.5)
Negative (0–1) 140 (58.8) 344 (65.6) 186 (82.3) 0.2179
Unknown 42 (17.6) 141 (26.9) 14 (6.2)
Follow-up, months
Median 49 81 64.5
Range 1–340 2–327 3–169
Abbreviations: ER, estrogen receptor; IHC, immunohistochemistry; PgR,
progesterone receptor; YTMA, Yale tissue microarray (cohort).
doi:10.1371/journal.pone.0036559.t001
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PLoS ONE | www.plosone.org 5 May 2012 | Volume 7 | Issue 5 | e36559Figure 3. Comparison between ESR1 and ER protein on Yale breast cancer cohorts. The natural log of the nuclear ER AQUA score
determined by QIF using SP1 is shown on the y-axis and the AQUA score for ESR1 determined by qISH is on x-axis for YTMA 128, n=167 with scores
for both SP1 and ESR1 (A) and YTMA 130 1993–2005 Subset, n=195 with scores for both SP1 and ESR1 (B). The dotted line represents the threshold
for ER protein positivity. (C) Representative images from 4 cases on YTMA 128 for cytokeratin (green), DAPI (blue), and ESR1 or ER SP1 (red).
doi:10.1371/journal.pone.0036559.g003
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MA) was added to TBS/Tween and incubated for 1 hr at room
temperature. Membranes were washed with TBS/Tween and
then incubated with horseradish peroxidase–conjugated goat anti-
rabbit secondary antibody (Jackson ImmunoResearch Laborato-
ries, Inc., West Grove, PA) at a dilution of 1:5,000 for 1 hour at
room temperature. Bands were detected using SuperSignal West
Pico Substrate (Pierce, Rockford, IL) and exposed to film.
Immunofluorescence Staining
TMAs were stained with cytokeratin, DAPI and ER (SP1
1:1000) using a standard protocol developed in our laboratory and
recently described [15,19].
Quantitative Analysis
The AQUAH method of quantitative immunofluorescence
(QIF) is a method that allows exact and objective measurement
Figure 4. ESR1 predicts response to tamoxifen on YTMA 130 Subset. Kaplan-Meier curves all show 10-year recurrence-free survival. (A) Cases
from the YTMA 130 Subset were split by the median ESR1 AQUA score and shows no prognostic value. (B) ESR1 high (AQUA .4.13) cases from the
YTMA 130 Subset were split by tamoxifen treatment status. ESR1 high patients who received tamoxifen had a statistically significant reduced risk of
recurrence. (C) ESR1 low (AQUA ,4.13) cases from the YTMA 130 Subset were split by tamoxifen treatment status and show no statistically significant
trend. (D) ER positivity on YTMA 130 determined by QIF with SP1 is prognostic. (E) ER positive cases from YTMA 130 were split by tamoxifen
treatment status. Patients who received tamoxifen had a reduced risk of recurrence trending towards significance. All p values were calculated using
the log-rank test.
doi:10.1371/journal.pone.0036559.g004
Table 2. Multivariate Analysis for YTMA 130 Subset.
Variable (n=126) HR (95% CI) p-value
Age
,50 1.00
.50 0.576 (0.20–1.63) 0.2983
Tumor Size
,2 cm 1.00
2–5 cm 1.338 (0.46–3.92) 0.2314
Nodal Status
Negative 1.00
Positive 3.629 (1.17–11.24) 0.0255
PgR
Negative 1.00
Positive 1.179 (0.25–5.67) 0.8375
Her2
Negative 1.00
Positive 1.437 (0.48–4.32) 0.3371
ER (SP1)
Nuclear AQUA ,361 1.00
Nuclear AQUA .361 0.14 (0.04–0.539) 0.0043
ER (ESR1) 1.331 (0.83–2.13) 0.2314
Abbreviations: ER, estrogen receptor; IHC, immunohistochemistry; PgR,
progesterone receptor.
doi:10.1371/journal.pone.0036559.t002
Table 3. Multivariate Analysis of ER protein and ER mRNA for
YTMA 130 Subset.
Variable (n=126) HR (95% CI) p-value
ER (SP1)
Nuclear AQUA ,361 1.00
Nuclear AQUA .361 0.169 (0.05–0.54) 0.0028
ER (ESR1) 1.360 (0.91–2.04) 0.1372
Abbreviation: ER, estrogen receptor.
doi:10.1371/journal.pone.0036559.t003
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within subcellular compartments, as described elsewhere [20].
Briefly, a series of monochromatic high-resolution images were
captured using an Olympus AX-51 epifluorescent microscope
using a previously described algorithm for image collection [20].
For each histospot an in and out-of-focus image were obtained for
each fluorescence channel, DAPI (nuclei), Alexa 546 (cytokeratin),
or Cy5 (target probe). A tumor mask was created by binarizing the
cytokeratin signal and target probe expression was quantified only
in the tumor. AQUA scores were calculated for a given target
within the tumor mask by dividing the signal intensity by the area
of the tumor mask within the histospot. Patient sample histospots
with less than 5% tumor, determined by the percentage area
positive for cytokeratin were excluded from the analysis.
Statistical Analysis
Time series testing followed by simple exponential smoothing
was done using JMP 9 (SAS Institute). All other statistical testing
was done using StatView 5.0 (SAS Institute) software. Kaplan-
Meier survival analyses were performed for recurrence free
survival and statistical significance was assessed by using the log-
rank test. Multivariate analysis using the Cox proportional hazards
model was performed to assess the independent prognostic
significance of ESR1 on recurrence free survival.
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